8 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 8 of 8 clinical reviews.
A clinical and regulatory guide to oral minoxidil compounding legality, covering FDA approval history, 503A and 503B pharmacy pathways, Loniten labeling, off-label prescribing for hair loss, and safety data.
A clinical review of FDA Adverse Event Reporting System (FAERS) data on low-dose oral minoxidil, including cardiovascular signals, pericardial effusion reports, and how prescribers should interpret real-world pharmacovigilance findings.
A full regulatory timeline of oral minoxidil, from its 1979 FDA approval for hypertension to its off-label use in low-dose hair loss therapy, including label requirements and safety data.
A comprehensive review of oral minoxidil's regulatory status worldwide, including FDA approval history for hypertension, off-label low-dose prescribing for hair loss, and how regulators in Australia, the EU, and beyond handle this drug.
A comprehensive review of oral minoxidil (low-dose) label updates from 2020 through 2026, covering FDA safety communications, off-label dermatologic use, cardiovascular monitoring requirements, and emerging clinical data.
A complete guide to the regulatory and legal history of oral minoxidil, covering FDA approval timelines, labeling requirements, patent expiry, compounding status, and post-market safety surveillance obligations.
A clinical overview of the oral minoxidil regulatory pipeline, upcoming trials, next-generation formulations, and the future of low-dose oral minoxidil for hair loss treatment.
A clinical comparison of how the FDA and EMA regulate oral minoxidil for hair loss, including approval history, labeling, off-label prescribing trends, and safety monitoring requirements.